A BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) is an integrated fund and award framework to accelerate the translation of early-stage drug discovery from academia to pharma. The goal of our BRIDGE pre-seed partnerships is to unlock the potential of academic innovation from therapeutic concept to investable data point by making our know-how in drug discovery, our technology platforms and matched funding readily available to academic researchers.
Our BRIDGEs Fall Into Two Categories:
Accelerating the generation of start-up companies & licensing opportunities by:
- Systematically probing first- or best-in-class therapeutic concepts on our technology platforms
- Overcoming the poor reproducibility of published data on drug discovery by academia
- Catering to the growing interest by universities to create sustainable start-up companies
- Shortening timelines from idea to preclinical proof-of-concept and follow-on funding
To date, we have built BRIDGE partnerships across 3 continents with more than 40 top-tier academic partners and a diverse cohort of investors, including pharma companies, venture capital funds and governments.
Creating partnerships based on complementarity, mutual trust and an honest assessment of respective weaknesses, will improve efficiency, as amply demonstrated by Evotec’s BRIDGE program.
How to Accelerate Translational Drug Discovery
- Is Academic Research a Valid Source of Novel Medicines? >
- Finding a Winning Formula to Lower Carriers for Academic Researchers >
- Navigating the Tough Roadmap of Pre-seed Therapeutics Investment >
- A Day in the Life of a BRIDGE Expert in Residence >
- Access the Full Whitepaper >
